Clinical Trials Sponsored by Sichuan Cancer Hospital and Research Institute

Total 5185 results

Sun Yat-sen University
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy (ENCORE)

Nasopharyngeal Carcinoma

China
AC Camargo Cancer Center
H. Lee Moffitt Cancer Center and Research Institute

Completed

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

Neuroendocrine Tumors | Estrogen Receptor Positive Tumor | Progesterone Receptor Positive Tumor

United States, Brazil
Cancer Prevention and Research Institute, Italy

Unknown

Innovation in Mammography: Tomosynthesis Pathways (IMPETO)

Breast Cancer

Italy
Brigham and Women's Hospital
Dana-Farber Cancer Institute; Duke University; H. Lee Moffitt Cancer Center and...

Not yet recruiting

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors (PATH-4)

Hematopoietic Stem Cell Transplant

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Brigham and Women's Hospital; Amgen; H. Lee Moffitt...

Completed

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Neuroendocrine Tumor | Carcinoid Tumor | Pancreatic Neuroendocrine Tumor

United States
Cancer Institute and Hospital, Chinese Academy...
Zhejiang Cancer Hospital; Sun Yat-sen University; Shanghai Zhongshan Hospital; Fujian... and other collaborators

Unknown

Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy

Esophageal Cancer

China
H. Lee Moffitt Cancer Center and Research Institute
Patient-Centered Outcomes Research Institute

Completed

Navigator Guided e-Psychoeducational Intervention

Prostate Cancer

United States
Cancer Institute and Hospital, Chinese Academy...
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd

Terminated

Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer

Advanced Cancer
H. Lee Moffitt Cancer Center and Research Institute
GlaxoSmithKline

Recruiting

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Penile Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene

Recruiting

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Prostate Cancer | Stage IV Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Active, not recruiting

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Renal Cell Carcinoma Stage IV

United States
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Breast Cancer | Hormone Receptor Positive Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention

Graft Versus Host Disease | GVHD

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Prostate Cancer | Prostate Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene

Completed

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Terminated

Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

Liver Cancer

United States
Sichuan J.Z. Bio-chemical Science and Technology...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer

Advanced Lung Cancer

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
H. Lee Moffitt Cancer Center and Research Institute
Pediatric Cancer Foundation

Completed

Metformin in Children With Relapsed or Refractory Solid Tumors

Solid Tumors | Primary Brain Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
Reliable Cancer Therapies

Terminated

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

Pain | Lymphoma | Cancer | Neoplasm Metastasis | Multiple Myeloma | Hematologic Malignancy | Tumor | Unresectable Malignant Neoplasm | Malignant Solid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); Upjohn

Completed

Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)

Lymphoma | Leukemia

United States
Shandong Cancer Hospital and Institute

Recruiting

WASPE Sleep Adjustment for Children Aged 0-4 Years Undergoing Radiation Therapy

Pediatric Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer

Esophageal Cancer | Epigallocatechin Gallate | Dysphagia, Esophageal

China
Shandong Cancer Hospital and Institute

Recruiting

Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC

Neoadjuvant Therapy | Resectable Lung Non-Small Cell Carcinoma | IMMUNOTHERAPY | Biomarkers / Blood

China
Shandong Cancer Hospital and Institute

Recruiting

Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

Pancreas Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

Solid Tumor

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Shandong Cancer Hospital and Institute

Recruiting

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

Limited Stage Small Cell Lung Cancer

China
Shandong Cancer Hospital and Institute

Recruiting

Metabolomics Explores Biomarkers for Metastatic Breast Cancer

Breast Cancer

China
Shandong Cancer Hospital and Institute

Not yet recruiting

Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Not yet recruiting

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

Metastatic Breast Cancer
Shandong Cancer Hospital and Institute

Unknown

Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC

Metastatic Breast Cancer | HER2-positive Breast Cancer
Shandong Cancer Hospital and Institute

Unknown

Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer

Breast Cancer | Sentinel Lymph Node

China
Shandong Cancer Hospital and Institute

Unknown

A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Non-Small-Cell Lung Cancer
Shandong Cancer Hospital and Institute

Unknown

Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy

Lung Neoplasms | Esophagitis | Prevention & Control | Epigallocatechin Gallate
Shandong Cancer Hospital and Institute

Unknown

Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis

Epigallocatechin Gallate | Radiation Mucositis | Radio Dermatitis
Shandong Cancer Hospital and Institute

Unknown

Temperature and Injury in Radiotherapy Radiation Skin Injury

Breast Neoplasm Female | Radiation Toxicity
Shandong Cancer Hospital and Institute

Available

Oral Green Tea Extract for Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Shandong Cancer Hospital and Institute

Unknown

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

Carcinoma, Non-Small-Cell Lung

China
Shandong Cancer Hospital and Institute

Unknown

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients (CRAGMOLC)

Carcinoma, Non-Small-Cell Lung

China
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive (IMSLNB-CANP)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Withdrawn

Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node (Z0011-China)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Completed

Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative (IMSLNB-EBCP)

Breast Cancer

China
Shandong Cancer Hospital and Institute

Completed

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Cervical Cancer | Stomach Cancer | Breast Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Ovary Cancer | Malignancies

China
Shandong Cancer Hospital and Institute

Unknown

Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients

Chronic Hepatitis B | Dysplastic Nodule of Liver
Shandong Cancer Hospital and Institute

Unknown

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival

China
Shandong Cancer Hospital and Institute

Unknown

A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

Glioblastoma

China

Clinical Trials Sponsored by Sichuan Cancer Hospital and Research Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations